Core Scientific Inc vs Zimmer Biomet Holdings Inc — how do they compare? Core Scientific Inc trades at $21.4 (market cap $7.02B), while Zimmer Biomet Holdings Inc trades at $90.7 (market cap $17.61B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.5× Core Scientific Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.05% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals.
| CORZ | ZBH | |
|---|---|---|
Market Cap | $7.02B | $17.61B |
Sector | Technology | Health |
52-Week High | $29.16 | $107.71 |
52-Week Low | $12.65 | $79.58 |
Enterprise Value | $8.07B | $24.66B |
Dividend Yield | — | 1.05% |
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $22.71, down 3.32% today, with a bearish technical signal despite strong analyst support. The company is transitioning from Bitcoin mining to AI colocation, with Q1 2026 colocation revenue surging to $77.5M and gross margins of 57%. However, the company continues to report significant losses with a net income margin of -341.68% and negative cash flow of $525.6M in 2025.
The outlook remains speculative with substantial execution risk despite analyst optimism. While the AI pivot offers growth potential, persistent losses and cash burn present significant challenges. The consensus price target of $34.17 suggests 50% upside potential, but investors must weigh the high-risk transformation against the company's current financial instability.
Zimmer Biomet (ZBH) trades at $94.08, up 3.0% in the past 24 hours, near its consensus price target of $97.67. The stock shows bullish technical signals with strong moving average support and has consistently beaten earnings estimates in recent quarters. Revenue grew to $8.23B in 2025, though net income margin declined to 8.56%. Recent corporate developments include expansion in Asia Pacific and a planned $1 billion share repurchase program in 2026.
ZBH presents a balanced outlook with steady revenue growth and shareholder returns via dividends and buybacks, but faces risks from margin compression and rising debt. Analyst sentiment is mixed with 40% buy ratings, suggesting moderate upside potential with caution around profitability trends and competitive pressures in the medical device sector.
Trailing returns across standard periods
Latest headlines on both assets
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →